ALK's partner Torii submits NDA in Japan for house dust mite sublingual tablet

26 January 2015

Denmark-based allergy specialist ALK Abello’s (ALKB: DC) Japanese partner, Torii Pharmaceutical (TYO: 4551), has submitted a New Drug Application in Japan for ALK’s house dust mite sublingual allergy immunotherapy tablet for the indication of allergic rhinitis.

The NDA has been submitted to the Japanese Ministry of Health, Labor and Welfare as part of ALK’s partnership with Torii, which covers the development, registration and commercialization of the house dust mite SLIT-tablet, and one against Japanese cedar pollen allergy.

The HDM tablet is under review by the European authorities.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK